Abstract:
FIG. 1 is a perspective view of a stent showing our new design; FIG. 2 is another perspective view thereof; FIG. 3 is front view thereof; FIG. 4 is a rear view thereof; FIG. 5 is a right-hand view thereof; FIG. 6 is a left-hand view thereof; FIG. 7 is a top view thereof; FIG. 8 is a bottom view thereof; FIG. 9 is another front view thereof; and, FIG. 10 is a cross-sectional view along each of lines 10-10 shown in FIG. 9. The broken lines illustrate portions of the patmas lantern stent that form no part of the claimed design.
Abstract:
This disclosure relates to compounds and methods of treating or preventing a Nox related disease or condition comprising administering to a subject in need thereof a Nox inhibitor or pharmaceutical compositions comprising a Nox inhibitor disclosed herein, derivatives, or compounds disclosed herein optionally substituted with one or more substitutes including optional salt and prodrug forms. In certain embodiments, this disclosure relates to sulfonylurea compounds and uses reported herein.
Abstract:
A transdermal delivery system of microneedles containing a bioactive material, comprising at least one layer of a support material; at least one biodegradable needle associated with the support material, each needle comprising at least one biodegradable polymer and at least one sugar, wherein each biodegradable needle is hollow and is adapted to retain a bioactive material.
Abstract:
Transdermal patches and transdermally applyable pharmaceutical compositions containing an effective amount of at least one drug are disclosed. The at least one drug may be: (a) phenmetrazine; (b) 4-benzylpiperidine; (c) 3-flouroamphetamine; (d) a DA/NE releaser compound having formula (I): wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 is independently hydrogen, a halogen, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted alkoxy group, and when one or more substituents is present on an alkyl group, an alkoxy group, or both, each substituent is independently a halogen; or (e) any combination thereof. Methods of making transdermal patches and transdermally applyable pharmaceutical compositions and methods of using transdermal patches and transdermally applyable pharmaceutical compositions are also disclosed.
Abstract:
Vitamin E-based amphiphilic copolymers are disclosed. Compositions containing vitamin E-based amphiphilic copolymers and/or nanocarriers are also disclosed. Methods of making vitamin E-based amphiphilic copolymers and/or nanocarriers and methods of using vitamin E-based amphiphilic copolymers and/or nanocarriers are also disclosed.
Abstract:
Embodiments provide for health related inquires, such as inquiries for information about a drug, disease, or other condition, to be received and responses to the inquiries to be delivered to the requester. The inquiries may be submitted electronically and the response may likewise be returned electronically. It may be determined whether the requester is a healthcare provider or a patient and the formulation of the response proceeds based on which type of requester submitted the inquiry. Delivery characteristics may be specified for the inquiry such as the delivery type and a timeframe for delivery. An account may be provided for requesters to provide information including a default delivery type and credentials to establish the requester type. Additional features may be provided including newsfeed subscriptions related to the inquiry to provide ongoing information subsequent to the submission of the inquiry.
Abstract:
A method for forming microspheres containing bioactive material, comprising dissolving a polymer matrix, such as albumin or beta-cyclodextrin, in an aqueous medium in a first vessel; contacting the dissolved polymer matrix with a crosslinking agent, such as glutaraldehyde, to crosslink the polymer matrix and the crosslinking agent; neutralizing with sodium bisulfate any excess crosslinking agent remaining after crosslinking is substantially complete; solubilizing in a second vessel a bioactive material in an aqueous solution; mixing the solubilized bioactive material together with the neutralized crosslinked polymer matrix in solution to form a mixture; and, spray drying the mixture to produce nanospheres, whereby substantial bioactivity of the biomaterial is retained upon cellular uptake.
Abstract:
A method for forming microspheres containing bioactive material, comprising dissolving a polymer matrix, such as albumin or beta-cyclodextrin, in an aqueous medium in a first vessel; contacting the dissolved polymer matrix with a crosslinking agent, such as glutaraldehyde, to crosslink the polymer matrix and the crosslinking agent; neutralizing with sodium bisulfate any excess crosslinking agent remaining after crosslinking is substantially complete; solubilizing in a second vessel a bioactive material in an aqueous solution; mixing the solubilized bioactive material together with the neutralized crosslinked polymer matrix in solution to form a mixture; and, spray drying the mixture to produce nanospheres, whereby substantial bioactivity of the biomaterial is retained upon cellular uptake.
Abstract:
A method of transdermal delivery of a vaccine, comprising preparing microparticles of encapsulated vaccine by spray drying a mixture of the vaccine and at least one polymer, and injecting the microparticles transdermally using a microneedle delivery apparatus.
Abstract:
Compounds, such as cathinone derivatives, and pharmaceutical formulations that include the compounds. The compounds may have a first selectivity for a first receptor subtype that is at least 10 times greater than a second selectivity for a second receptor subtype from the same class of receptors. Methods of treating patients, which may include administering to a patient a pharmaceutical formulation that includes a compound, such as a cathinone derivative.